EE349 Cost-Effectiveness of First-Line Treatment With Pembrolizumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer (CRC) in the United States Based on 5-Year Follow-up Data
Abstract
Authors
G McCarthy G Baluni N Chhabra D Bhadra R Xu M Chaudhuri R Massaad M Amonkar